GuidelinePostgraduate medical journal1993
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.
Guideline in Postgraduate medical journal, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.Heart (British Cardiac Society) · 1998Guideline
- The acceptability of resin therapy to patients attending a hospital lipid clinic.British journal of clinical pharmacology · 1995Trial
- Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants.BMJ (Clinical research ed.) · 1995Trial
- Changes in blood pressure and lipids associated with rural to urban migration in Tanzania.Journal of human hypertension · 2006Article
- Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics.British journal of clinical pharmacology · 2003Article
- Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation.British journal of clinical pharmacology · 2003Article
- CORONARY RISK ANALYSIS - A STITCH IN TIME.Medical journal, Armed Forces India · 2002Article
- The current status of primary prevention in coronary heart disease.Current controlled trials in cardiovascular medicine · 2001Article
- Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey.BMJ (Clinical research ed.) · 2000Article
- Drugs used in secondary prevention after myocardial infarction: case presentation.British journal of clinical pharmacology · 2000Review
- Observed changes in the lipid profile and calculated coronary risk in patients given dietary advice in primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2000Article
- Use of antithrombotic measures for stroke prevention in atrial fibrillation.Heart (British Cardiac Society) · 1999Article
- Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy. An illustrative example focusing on the primary prevention of coronary heart disease in Canada.PharmacoEconomics · 1999Article
- Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors.BMJ (Clinical research ed.) · 1998Article
- Indicators of the appropriateness of long-term prescribing in general practice in the United Kingdom: consensus development, face and content validity, feasibility, and reliability.Quality in health care : QHC · 1998Article
- The potential role of soluble fibre in the treatment of hypercholesterolaemia.Postgraduate medical journal · 1998Review
- Management of lipids in the elderly.Journal of the Royal Society of Medicine · 1998Review
- Intensive cardiovascular risk factor intervention in a rural practice: a glimmer of hope?The British journal of general practice : the journal of the Royal College of General Practitioners · 1998Article
- Low levels of cardiovascular risk factors and coronary heart disease in a UK Chinese population.Journal of epidemiology and community health · 1997Article
- ACP Broad Sheet no 151: September 1997. Investigation of dyslipidaemias.Journal of clinical pathology · 1997Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is considerable evidence to suggest that the identification and treatment of dyslipidaemia will reduce the risk of premature CHD, i.e. before the age of 65. Diagnosis of the cause of raised plasma lipid levels will enable appropriate decisions to be taken with regard to management. The cornerstone of treatment is nutritional counselling and attention to other major risk factors for CHD, particularly smoking and hypertension. For a small percentage of patients with severe hyperlipidaemia drug therapy is indicated. Appropriate drug choices need to be made based on the particular lipid abnormality to be treated. In general those patients with clinical vascular disease are treated more aggressively than those where the aim is primary prevention. More research is needed to determine individual risk more precisely and to allow proper targeting of therapy. Genetic factors, qualitative changes in lipoproteins, lipoprotein (a), fibrinogen, and other coagulation and thrombotic factors are likely to be important in individual risk assessment. There is no doubt that more information is needed from prospective studies of lipid-lowering therapy in terms of risk benefit for affected individuals. Hopefully the major studies currently underway will fill some of the gaps in our knowledge. Until then aggressive therapy with drugs should be reserved for those at highest risk where the benefit is likely to be greatest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.